Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease.

Archive ouverte

Raverdy, Violeta | Tavaglione, F. | Chatelain, Estelle | Lassailly, Guillaume | de Vincentis, A. | Vespasiani-Gentilucci, U. | Qadri, S. F. | Caiazzo, Robert | Verkindt, Hélène | Saponaro, Chiara | Pattou Kerr-Conte, Julie | Baud, Gregory | Marciniak, Camille | Chetboun, Mikael | Oukhouya-Daoud, Naima | Blanck, Samuel | Vandel, Jimmy | Olsson, L. | Chakaroun, R. | Gnemmi, Viviane | Leteurtre, Emmanuelle | Lefebvre, Philippe | Haas, Joel | Yki-Järvinen, H. | Francque, S. | Staels, Bart | Le Roux, C. W. | Tremaroli, V. | Mathurin, Philippe | Marot, Guillemette | Romeo, Stefano | Pattou, Francois

Edité par CCSD ; Nature Publishing Group -

International audience. Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits considerable variability in clinical outcomes. Identifying specific phenotypic profiles within MASLD is essential for developing targeted therapeutic strategies. Here we investigated the heterogeneity of MASLD using partitioning around medoids clustering based on six simple clinical variables in a cohort of 1,389 individuals living with obesity. The identified clusters were applied across three independent MASLD cohorts with liver biopsy (totaling 1,099 participants), and in the UK Biobank to assess the incidence of chronic liver disease, cardiovascular disease and type 2 diabetes. Results unveiled two distinct types of MASLD associated with steatohepatitis on histology and liver imaging. The first cluster, liver-specific, was genetically linked and showed rapid progression of chronic liver disease but limited risk of cardiovascular disease. The second cluster, cardiometabolic, was primarily associated with dysglycemia and high levels of triglycerides, leading to a similar incidence of chronic liver disease but a higher risk of cardiovascular disease and type 2 diabetes. Analyses of samples from 831 individuals with available liver transcriptomics and 1,322 with available plasma metabolomics highlighted that these two types of MASLD exhibited distinct liver transcriptomic profiles and plasma metabolomic signatures, respectively. In conclusion, these data provide preliminary evidence of the existence of two distinct types of clinically relevant MASLD with similar liver phenotypes at baseline, but each with specific underlying biological profiles and different clinical trajectories, suggesting the need for tailored therapeutic strategies.

Suggestions

Du même auteur

Performance of non-invasive tests for liver fibrosis resolution after bariatric surgery

Archive ouverte | Raverdy, Violeta | CCSD

International audience

Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study.

Archive ouverte | Raverdy, Violetta | CCSD

International audience. Objective:Steatotic liver disease (SLD) is frequent in individuals with obesity. In this study, type 2 diabetes (T2D), sex, and menopausal status were combined to refine the stratification of...

Resolution of MASH with no worsening of fibrosis after bariatric surgery improves 15-year survival: a prospective cohort study.

Archive ouverte | Lassailly, Guillaume | CCSD

International audience. ObjectivesInvestigate the consequences of the histological progression of metabolically associated steatohepatitis (MASH) and fibrosis on long-term survival after bariatric surgery.MethodsFro...

Chargement des enrichissements...